Limited spots remain for the ATN Innovation Summit.
Secure your spot and join 750+ industry executives on June 16 & 17 in NYC.
A new report from Hims & Hers underscores the urgency of weight loss for Americans as companies race to distribute weight loss medications.
Hims & Hers has added protein-packed meal replacement bars and shakes for GLP-1 users and those focused on weight management.
Hims & Hers has released a white paper showing that 87% of its GLP-1 weight loss program customers are close to their goal or have met it.
As GLP-1 drugs surge, here's how telehealth companies and brick-and-mortar fitness giants are responding to the Ozempic era.
JP Morgan Private Capital has raised over $500 million for a life sciences fund targeting private biotech companies and the booming weight-loss drug space.
Hims & Hers will now provide access to compounded GLP-1s for eligible consumers at a discounted rate compared to brand-name prescriptions.
Hims' new platform will roll out just in time for New Year’s resolutions, but will lean on generic medications instead of highly popular GLP-1s.
The new funding allows Define Ventures to continue its track record of investing in promising early-stage digital health startups.
Allermi offers a customized, all-in-one nasal spray designed to offer relief to all types of allergy sufferers.
Hims & Hers products on Amazon will include biotin, immunity & sleep gummies, collagen powder supplements, sexual health & wellness products..
Sign Up to Our Newsletter
